Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Shivendra V. Singh

Shivendra V. Singh

Professor/Associate Director USA

Dimitrios H. Roukos

Dimitrios H. Roukos

Founding Director Greece

Alexander Buko

Alexander Buko

Vice President USA

David I Smith

David I Smith

Professor & Chairman USA

Azza Mahmoud Kamel

Azza Mahmoud Kamel

Emirate Professor Egypt

Yiu-Lian Fong

Yiu-Lian Fong

Senior Director, Global Diagnostic Innovation UK

Sadir J Al Rawi

Sadir J Al Rawi

Director of Surgical Oncology UAE

Jose J. Jimenez-Moleon

Jose J. Jimenez-Moleon

Director and Associate professor Spain

Liquid biopsy Biomarker 2018

About the conference

About Conference

Conference Series Ltd invites all the doctors, professors, researchers, scientific communities, therapists, delegates, students, business professionals and executives across the world to attend the 22nd World Conference on Liquid Biopsy & Biomarkers during October 15-16, 2018 Toronto, Canada.

The clinical approaches of precision medicine are wide, encompassing screening, prognosis, diagnosis, prediction of treatment response and resistance, early detection of recurrence/metastasis and biologic cancer stratification. Liquid biopsies are generally considered   non-invasive tool for biomarker discovery that is gaining significant attention. The development of a non-invasive “liquid biopsy” represents a remarkable innovation in the field of precision medicine. Emerging interests in the field of liquid biopsies have encouraged researchers to recognize and develop clinically relevant noninvasive genomic and epigenomic signatures that can be exploited as biomarkers capable of detecting premalignant and early-stage cancers.

Biomarkers may be produced by both normal cells and abnormal cells especially cancerous cells, are biologically active compounds or molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal cellular processes, or of a condition disease that is useful for diagnostics, prognostics, therapeutics and theranostics.

In cancer patients, Biopsies provide the histological explanation, of the disease and, currently, have revealed details of the genetic profile of the tumor enabling prediction of cancer progression and response to therapies. The role of CT-guided core biopsy has increased in the diagnosis of benign disease, cellular differentiation, and somatic mutation analysis. A fine-needle aspiration (FNA) biopsy is often used to take cell samples from organs or from lumps that are below the surface of the skin.

Being inherently unique, limited and non-renewable, after a limited number of analyses, small samples of tissue biopsies gets completely exhausted. A method has been introduced that enables fast and reproducible conversion of a small amount of tissue (approximating the quantity obtained by a biopsy) into a single, permanent digital file representing the mass spectrometry-measurable proteome of the sample. The method combines pressure cycling technology (PCT) and SWATH mass spectrometry (MS), and the resulting proteome maps can be analyzed, re-analyzed, compared and mined in silicon to detect and quantify specific proteins across multiple samples.

Why to attend Liquid biopsy and biomarkers 2018?

22nd World Conference on Liquid Biopsy & Biomarkers provides a great platform for doctors, researchers, professors, students, contributors, business professionals and industrialists to exchange ideas, communicate and discuss the applications of liquid biopsy and biomarkers in the field of health care. Many doctors, scientists, researchers and world’s renowned experts will participate in this conference. The aim of this conference with theme accelerating researches in Liquid Biopsy & Biomarkers is focusing on the genomics of cancer and the advantages of non-invasive techniques in health care sectors.

Target Audience

  • Doctors
  • Cancer Specialist
  • Medical Oncologist
  • Surgeons
  • Academic Scientists
  • Research faculty
  • Radiology Technicians
  • Pathologists
  • Clinicians
  • Young Researchers
  • Industrial professionals from biomedical and healthcare sectors
  • Students
  • Biotechnology Companies
  • Government and Public Laboratories
  • Liquid Biopsy Product Manufacturers and Distributors
  • Reference Laboratories and Institutes
  • Pharmaceutical Companies
  • Hospitals and Diagnostics Centers

Conference highlights

  • Oncology & Molecular Pathology
  • Cancer Diagnostics
  • Biopsy: Scans & Tests
  • Breast Cancer and Biopsy
  • Advances in Liquid Biopsy
  • Liquid Biopsy: Emerging Biomarkers
  • Cancer Biomarkers
  • Liquid Biopsy: Technological Innovations
  • Cancer Cell Biology
  • Cancer Genetics & Epigenetics
  • Cancer: Drugs & Treatments
  • Protein Kinase (CDK) & Cancer Therapy
  • Cancer Statistics
  • Tumor Cell:  Migration and Invasion
  • Cancer Stem Cells
  • Stem Cell Transplantation
  • Stem Cell Engineering
  • Radiology: Nuclear Medicine & Imaging
  • Metastasis Biology
  • Pediatric Cancer: Leukemia
  • Neurological Cancer
  • Tumor Microenvironment and EMT
  • Tumor Cells: Migration and Invasion
  • Oncogenes and Signal Transduction
  • Cancer Cell Metabolisms
  • Biomaterials: Vaccine and Immunotherapy
  • Alternative Medicine & Cancer



Track 1: Oncology & Molecular Pathology

Track 2: Cancer Diagnostics

Track 3: Biopsy: Scans & Tests

Track 4: Breast Cancer and Biopsy

Track 5: Advances in Liquid Biopsy

Track 6: Liquid Biopsy: Emerging Biomarkers

Track 7: Cancer Biomarkers

Track 8: Liquid Biopsy: Technological Innovations

Track 9: Cancer Cell Biology

Track 10: Cancer Genetics & Epigenetics

Track 11: Cancer: Drugs & Treatments

Track 12: Protein Kinase (CDK) & Cancer Therapy

Track 13: Cancer Statistics

Track 14: Tumor Cell:  Migration and Invasion

Track 15: Cancer Stem Cells

Track 16: Stem Cell Transplantation

Track 17: Stem Cell Engineering

Track 18: Radiology: Nuclear Medicine & Imaging

Track 19: Metastasis Biology

Track 20: Pediatric Cancer: Leukemia

Track 21: Neurological Cancer

Track 22: Tumor Microenvironment and EMT

Track 23: Oncogenes and Signal Transduction

Track 24: Cancer Cell Metabolisms

Track 25: Biomaterials: Vaccine and Immunotherapy

Track 26: Alternative Medicine & Cancer

Market Analysis

Importance & Scope

Increasing incidence of cancer, need for minimally invasive medical procedures, and increased spending for effective treatments are the major factors driving the global biopsy market. Statistics published on cancer shows that the global incidence of cancer in 2012 was 14.1 million which may reach to 23.6 million by 2030. The increasing number of cancer patients is set to increase the demand for biopsy procedures. Moreover, future projections indicate, even more, increase in prevalence, ensuring the lucrative industry growth in the coming years.

Market research analysts have estimated that the global biopsy devices market will keep on growing at a CAGR of more than 6% by 2020. Biopsy device Market Report predicts that the global biopsy market may reach $2,399 million by 2022, registering a CAGR of 5.5% during the period 2016-2022. According to the research report, the growing Non-Invasive Bone Marrow Aspiration Needle market is likely to boost the global market substantially over the forthcoming years.

Why Toronto, Canada?

Toronto is the leading tourism destination in Canada, attracting more than 25 million Canadian, American and international visitors annually. It is the provincial capital of Ontario and the fourth most populous city in North America after New York City, Mexico City, and Los Angeles. Toronto is the center of the Greater Toronto Area (GTA) which is the most populous metropolitan area in Canada. A global city, Toronto is an international center of finance, business, arts, and culture, and is recognized as one of the most cosmopolitan and multicultural cities in the world. Toronto is home to 20 public hospitals, including: Mount Sinai Hospital, St. Michael's Hospital, the Hospital for Sick Children, Toronto Western Hospital, North York General Hospital, Toronto General Hospital, St. Joseph's Health Centre, Rouge Valley Health System, The Scarborough Hospital, Sunnybrook Health Sciences Centre, Centre for Addiction and Mental Health (CAMH), and Princess Margaret Cancer Centre, as well as the University of Toronto Faculty of Medicine. The Ontario Institute for Cancer Research (OICR) and Princess Margaret Cancer Centre are the most popular Institute for Cancer Research in Canada. The Ontario Institute for Cancer Research (OICR) is a not-for-profit organization based in Toronto, Ontario, Canada that focuses on the early diagnosis, detection, prevention and treatment of cancer.

Biopsy Market Segmentation, By Procedural Type

  • Needle biopsy
  • Surgical biopsy 

Needle Biopsy

Needle biopsy market will grow at a CAGR of 5.2 % till 2023 for sure. Europe Clinical Reference Laboratory Market is projected to expand at a CAGR of 5.4% which may reach the US $ 1, 14,128.8 million by 2027. In 2016, Europe Clinical Reference Laboratory Market, Western Europe accounted for the largest market share.

Key players in the market are:

  • Boston Scientific Corporation
  • Cook Medical
  • CareFusion Corporation
  • Hologic Inc.
  • Cardinal Health Inc.
  • Medax
  • C. R. Bard Inc.
  • Möller Medical GmbH
  • Becton
  • Dickinson and Company
  • Hakko co. ltd.
  • Kompass
  • Argon Medical Devices Inc.

Vacuum-assisted needle biopsy has been estimated to be the fastest growing segment. According to the market study, the biopsy needle-based guns segments will have more influence in the biopsy devices throughout the forecast period and by 2020, will account for more than 41% of the total market share.

Surgical Biopsy

The surgical biopsy segment market value was $436.4 Million in 2015 and shared more than 56% of the total market and thus had more influence in the industry during 2015. The global breast biopsy market can smoothly reach $728.8 Million by 2020, at a CAGR of 10.8%.

The breast biopsy guidance market has been categorized as mammography, ultrasound, MRI, and others (PET and thermography). Owing to the increasing demand for minimally invasive and non-radiation breast biopsy among patients and surgeons, the ultrasound is estimated to be the fastest growing segment.

On the basis of region, the breast biopsy market is segmented into North Europe, Asia-Pacific, America, and the Rest of the World. North America accounted for the largest share of the breast biopsy market in 2015, followed by Europe. Asia-Pacific is expected to reach a higher rate of growth during the forecast period. The growth of the breast biopsy market in Asia-Pacific is mainly centered on India and China.

Major players operating in the market are:

  • C.R. Bard
  • Becton
  • Dickinson
  • Devicor Medical Products Inc. (U.S.)
  • Company (U.S.)
  • Inc. (U.S.)
  • Hologic Inc. (U.S.)

Biopsy Market Segmentation, By Product Type

  • Biopsy guidance systems
  • Biopsy needles
  • Biopsy needle-based guns
  • Biopsy forceps 

According to an estimate, vacuum assisted needle biopsy is going to be the fastest growing segment. The biopsy needle-based guns segments will have the highest influence in the biopsy devices throughout the predicted period and will hold more than 41% of the total market share by 2020.

Biopsy Device Market, By Region

North America contributed the global share by 55% in 2015 and thus was the largest regional industry in the field of biopsy devices, followed by Europe and Asia Pacific. U.S. In 2015, Biopsy devices market size has a value close to USD 1 billion, which was over 80% of the industries in North America. This was due to the increased awareness regarding cancer diagnosis, and continued funding activities for effective diagnostics procedures. Europe biopsy devices market share may see moderate growth, with Germany being responsible for over 28% sales in 2015. China and India biopsy devices market may enter the maximum growth rate of 11.8% from 2016 to 2024 and is eyed upon as the most beneficial market for investment. 

Biopsy Device Market

During the forecast period, CT-guided biopsy segment is expected to grow at the highest CAGR of 6.3%. The lung biopsy is expected to be the fastest growing application segment, entering a CAGR of 7.0%.The robotic guidance system segment is estimated to enter the highest CAGR of 7.0%.The Asia-Pacific region may become the fastest growing market, with a CAGR of 7.2%.

The key companies in the market are:

  • Leica Biosystems
  • C.R. Bard Inc.
  • Boston Scientific Corporation
  • Hologic Inc.
  • Becton
  • and Company
  • Ethicon EndoSurgery Inc.
  • Mauna Kea Technologies
  • Fujifilm Medical Systems
  • Veran Medical Technologies
  • MDxHealth
  • Cook Medical Inc
  • Dickinson
  • Argon Medical Devices Inc.
  • Intact Medical Corp.   

Biomarkers Market Analysis

The biomarkers market is segmented on the basis of product, type, disease indication, application and region. The global biomarkers market is estimated to reach USD 53.34 Billion by 2020 from USD 27.95 Billion in 2015, at a CAGR of 13.8% from 2016 to 2021. Whereas the global market of biomarkers for Diagnostic Applications is expected to garner USD 30.6 Billion globally by 2020, registering a CAGR of 16% during the forecast period 2013 to 2020.  Global biomarkers market figures are based on the revenues at the manufacturer’s level and are projected at 2013-dollar value. Trends are assessed based on projected sales for existing products, introductions of new products, expanded indications for existing products and projected changes in the prevalence, diagnosis and scripting rates for specific diseases.

                           Biomarkers market revenues share by segment, 2012 and 2020

Market Growth of Liquid Biopsy

Major complications associated with typical tumor biopsies for a variety of various cancers include infections, colonic perforation, peritonitis, and collapsed respiratory organ, inflammation of the pancreas, sepsis, and haematoma. Moreover, within the current scenario, a diagnostic test prices between USD 2000 to as high as USD 10,000. The increase in prices due to further treatment needed owing to the complications could drive this value up fourfold.


The rising incidence of cancer, pros of liquid Biopsy test over solid tumor diagnostic test, advancements in the technology, handiness of funding and growing awareness regarding biopsy through government initiatives and the conferences, are driving the expansion of the market. Some within the business predict the market’s worth may balloon to anyplace from $20 billion to over $100 billion. The liquid biopsy market is anticipated to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during this period.

A glance at Market of Advertising and Marketing

Multiple gene analysis using NGS technology expected to witness higher demand in this market over the forecast period. Some of the key players like Adaptive Biotechnologies, Biocept, Guardant Health, NeoGenomics Laboratories, Personal Genome Diagnostics, Qiagen, RainDance Technologies, Cynvenio, and Trovagene, have commercialized tests for CTC, ctDNA, and exosomes and are directly involved in the liquid biopsy.

Commercialization is expected to take place that will consequently fuel significant growth in revenue between 2020 to 2030.The Global Liquid Biopsy Market to expand at a CAGR of 20.31% during the period 2017-2021.CTCs and ctDNA hold immense potential for breakthrough developments in cancer care and in reducing cancer-related mortality.

To Collaborate Scientific Professionals around the World

Conference Date October 15-16, 2018

For Sponsors & Exhibitors

Speaker Opportunity

Past Conference Report

Supported By

Journal of Cancer Diagnosis

Diagnostic Pathology: Open Access

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by

Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos